Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma

Atalay, Funda; Taskiran, Cagatay; Taner, M. Zeki; Pak, Işın; Or, Melis; Tunçer, Serdar

doi:10.1111/j.1447-0756.2007.00663.x

Cited by 27 publications

(34 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding was in agreement with other study found that the presence of high-risk types of HPV was found in the serous histological subtype and advanced stages of the disease (FIGO stages III and IV) [39]. Other studies showed no evidence of high-risk HPV association with histological subtype and/or stage of disease [4,24].…”

Section: Discussionsupporting

confidence: 93%

Human papillomavirus genotyping and integration in ovarian cancer Saudi patients

Al‐Shabanah

Hafez

Hassan

et al. 2013

Virol J

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) is associated with different malignancies but its role in the pathogenesis of ovarian cancer is controversial. This study investigated the prevalence, genotyping and physical state of HPV in ovarian cancer Saudi patients.MethodsHundred formalin fixed paraffin embedded (FFPE) ovarian carcinoma tissues and their normal adjacent tissues (NAT) were included in the study. HPV was detected by nested polymerase chain reaction (PCR) using degenerated HPVL1 consensus primer pairs MY09/MY11 and GP5+/GP6 + to amplify a broad spectrum of HPV genotypes in a single reaction. The HPV positive samples were further genotyped using DNA sequencing. The physical state of the virus was identified using Amplification of Papillomavirus Oncogene Transcripts (APOT) assay in the samples positive for HPV16 and/or HPV18.ResultsHigh percentage of HPV (42%) was observed in ovarian carcinoma compared to 8% in the NAT. The high-risk HPV types 16, 18 and 45 were highly associated with the advanced stages of tumor, while low-risk types 6 and 11 were present in NAT. In malignant tissues, HPV-16 was the most predominant genotype followed by HPV-18 and -45. The percentage of viral integration into the host genome was significantly high (61.1%) compared to 38.9% episomal in HPV positive tumors tissues. In HPV18 genotype the percentage of viral integration was 54.5% compared to 45.5% episomal.ConclusionThe high risk HPV genotypes in ovarian cancer may indicate its role in ovarian carcinogenesis. The HPV vaccination is highly recommended to reduce this type of cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Human papillomavirus genotyping and integration in ovarian cancer Saudi patients

Al‐Shabanah

Hafez

Hassan

et al. 2013

Virol J

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated an association of HPV with ovarian cancers [2, 3, 51]. We detected molecular signatures of high risk HPV16 and 18 along with other low risk HPVs in the ovarian cancer samples screened.…”

Section: Discussionmentioning

confidence: 93%

The ovarian cancer oncobiome

et al. 2017

View full text Add to dashboard Cite

Humans and other mammals are colonized by microbial agents across the kingdom which can represent a unique microbiome pattern. Dysbiosis of the microbiome has been associated with pathology including cancer. We have identified a microbiome signature unique to ovarian cancers, one of the most lethal malignancies of the female reproductive system, primarily because of its asymptomatic nature during the early stages in development. We screened ovarian cancer samples along with matched, and non-matched control samples using our pan-pathogen array (PathoChip), combined with capture-next generation sequencing. The results show a distinct group of viral, bacterial, fungal and parasitic signatures of high significance in ovarian cases. Further analysis shows specific viral integration sites within the host genome of tumor samples, which may contribute to the carcinogenic process. The ovarian cancer microbiome signature provides insights for the development of targeted therapeutics against ovarian cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

“…So, previous studies have documented the increase of HPV-16 associated OCa in Iran. Atalay (2007) in Turkey reported 8.5 % HPV in OCa patients (21). Rosa et al (2013) in a meta-analysis study showed a range of 0% to 66.7% HPV prevalence with a mean of 17.5% in OCa patients and, more, reported the highest HPV prevalence in Asia at 31.4%.…”

Section: Discussionmentioning

confidence: 99%

“…The etiology of OCa is multifactorial; the main causes are genetic, environmental, and sexual behavior and HPV which is the main pathogen that leads to OCa (21). Previous studies report different ranges of HPV prevalence in OCa, even some studies were unable to detect HPV in OCa (21)(22)(23)(24). A wide range of study results do not demonstrate the exact prevalence of HPV and this could be because of different study conditions like the type of histopathology sampling, sample transferring and storage condition, the type of method that is used for HPV detection, molecular technique conditions, the time of the study, OCa stage, and patient conditions like age, race and ethnicity, sexual behavior, and the genetics.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of Human Papilloma Virus Type 16 in Epithelial Ovarian Tumors Samples

Dadashi

Eslami

Faghihloo

et al. 2016

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Ovarian carcinoma is the most common malignancy in women and is a cancer with a 15% -50% prevalence in the world. Human papilloma virus (HPV) is considered a factor in cervical and ovarian cancer (OCa) and is related to squamous cell carcinoma in the cervical region. The effect of fixed infection may cause chronic inflammation, in the cancer of ovaries it has received very rare attention, although a background of pelvic inflammatory disease (PID) in a case-control study is associated with a higher risk for ovarian carcinoma. HPV-16 is one type of HPV and the most common and important cause of cervical carcinoma in the developed world. Objectives: The aim of this investigation was to evaluate the incidence of HPV-16 in patients with OCa who referred to Imam Hossein hospital of Shahid Beheshti University of Medical Sciences, Tehran, Iran. Methods: In this case-control study that was conducted since May 2015 to October 2015 in Tehran, 140 samples were studied which were obtained from patients with OCa. After obtaining the samples from OCa tissue by a pathologist, for DNA extraction, samples were transferred to the laboratory of the university. DNA was extracted with Kit (intron biotechnology Co. Korea) according to the manufacturer's instructions. To confirm the presence of HPV-16 in the samples of OCa, specific primers for the L1 gene of HPV were designed and standard PCR method was used for the detection of HPV. PCR product was sequenced to confirm the presence of HPV-16. Results: Out of 140 samples of OCa, 70 (50%) samples were malignant cancer and 70 (50%) were benign cancer as the control group. Out of 70 malignant samples 25 (36.0%) were HPV-16 positive. 2.8% of the tissue samples of the control group were positive for HPV-16. Conclusions: These results show a feasible role of HPV-16 in the carcinogenesis of OCa. According to these results, infection with HPV may play a relative role in the spread of OCa or it could comfort its development.

show abstract

Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma

Abstract: HPV may have a role in the carcinogenesis of ovarian cancer. It is worth investigating this possible relation both in large case-control studies and in vitro models by using more sensitive techniques.

Cited by 27 publications

References 21 publications

Human papillomavirus genotyping and integration in ovarian cancer Saudi patients

Human papillomavirus genotyping and integration in ovarian cancer Saudi patients

The ovarian cancer oncobiome

Detection of Human Papilloma Virus Type 16 in Epithelial Ovarian Tumors Samples

Contact Info

Product

Resources

About